Ashley M. Stokes1, Natenael B. Semmineh1, and C. Chad Quarles1
1Translational Bioimaging Group, Barrow Neurological Institute, Phoenix, AZ, United States
Synopsis
Brain tumor dynamic susceptibility contrast (DSC)
MRI is adversely impacted by contrast agent leakage that results in confounding
T1 and T2* effects. While multi-echo acquisitions remove T1 leakage effects,
there is no consensus on the optimal set of acquisition parameters. Using a
validated DSC-MRI digital reference object (DRO), we assessed the influence of
preload dosing, pulse sequence parameters (number of echoes, TEs, TR, FA), and
leakage correction method on cerebral blood volume (CBV) accuracy. This
computational approach permits the systematic evaluation of a wide range of
acquisition strategies to determine the optimal multi-echo DSC-MRI perfusion
protocol.
Introduction
Relative cerebral blood volume (rCBV) measures
obtained from DSC-MRI are widely used in the diagnosis and treatment of brain
tumors [1,2]. However, contrast agent leakage effects can limit
the reliability of rCBV measurements [1,3]. Both acquisition (contrast agent dosing and pulse
sequence parameters) and post-processing methods have been proposed to minimize
or remove these effects. By acquiring multiple echoes [4], T1 leakage effects can be removed and may provide
more robust rCBV measures [5]. Unfortunately, there is no consensus on the optimal
set of acquisition parameters for multi-echo DSC-MRI, and experimentally
assessing these methods is challenging and impractical. The purpose of this
study is to leverage a digital reference object (DRO) to systematically
evaluate a wide range of acquisition strategies to determine the optimal multi-echo
DSC-MRI perfusion protocol. Methods
The details of the population-based DRO were
published previously [6]. Briefly, the DRO calculates the MR signal from
realistic 3D tissue structures, with the cells and vessels simulated as ellipsoids
packed around randomly oriented cylinders. To ensure clinical relevance, the
DRO was trained and validated using two distinct datasets from glioblastoma
patients. For this study, the DRO MRI data were simulated at 3T. To test the
optimal combination of echo times, four echo times were simulated (20, 30, 40,
and 50 ms). Each echo time was assessed individually (single-echo); dual-echo
combinations were 20 and 30 ms, 20 and 50 ms, and 40 and 50 ms. A multi-echo
(ME) fit to all 4 echoes was also assessed. The MRI protocol also included
three flip angles (30, 60, and 90°) and three repetition times (TRs, 1, 1.5,
and 2 s). Two injection protocols were simulated: no preload with single-dose
bolus (0+1) and single-dose preload and bolus (1+1). For each parameter
combination, the DRO produced 10,000 voxels with varying CA leakage effects. A
parallel set of 10,000 voxels was simulated without leakage (Ktrans = 0) for
each parameter combination. Leakage correction was performed using the standard
Boxerman-Schmainda-Weisskoff (BSW) method [7,8]. An accuracy and precision (AP) index, defined as the
concordance correlation coefficient (CCC) – |coefficient of variation (CV)|,
was used to determine the best possible parameter combinations. Results / Discussion
Figure 1 shows the single-echo and multi-echo
ΔR2* curves with and without preload and leakage correction (FA = 60°, TR =
1.5s). Although preload reduces T1 leakage effects for the single-echo
combinations, it further emphasizes T2* leakage effects for the multi-echo
combinations, as T1 leakage effects are inherently removed. The multi-echo ΔR2*
is highly consistent across all echo combinations for both dosing combinations.
Compared to the no leakage ΔR2*, both the uncorrected and BSW-corrected peak ΔR2* are reduced due to CA leakage, with the BSW
correction having the highest impact after the peak. The DRO rCBV maps are
shown in Figure 2 for all echo time combinations with and without preload and
leakage correction (FA = 60°, TR = 1.5s). T1 leakage effects lead to
underestimated rCBV for single-echo without preload, while T2* leakage effects
cause overestimation for single-echo with preload and all multi-echo
combinations with and without preload. Leakage correction improves rCBV
accuracy and appears to adequately correct T2* leakage effects. With multi-echo
acquisitions, the TE combination has minimal impact on rCBV, and multi-echo
acquisitions may obviate the need for preload dosing. The AP index was
calculated for all parameter combinations (TR, FA, and TE). Multi-echo is more
consistent and closer to 1 (optimal) than the single-echo options, with minimal
benefit from use of a preload. For multi-echo, the choice of TR and FA have
little impact on the AP index, indicating the potential for significant
flexibility in acquisition parameters. Inclusion of a shorter multi-echo TE
slightly improves AP index. BSW correction improves the AP index in all cases. Work
is ongoing to expand the DRO parameter space to a wider range of TEs, including
shorter TEs.Conclusions
Contrast agent extravasation reduces the
reliability of DSC-MRI brain tumor perfusion measures. Using a DRO, we have
systematically assessed four multi-echo combinations across two dosing schemes,
three TRs, three FAs, and one leakage correction method. Overall, the multi-echo
acquisitions were more robust than single-echo acquisitions. The dual-echo
combinations performed as well as the multi-echo fit, indicating that
additional echoes (>2) may not be necessary. The use of multi-echo
acquisitions provides significant pulse sequence flexibility, essentially
decoupling both TR and FA from rCBV accuracy. The DRO also demonstrates that multi-echo
acquisitions do not benefit from a preload injection. Finally, leakage
correction was found to improve rCBV accuracy in all cases. Acknowledgements
This work was supported by the Arizona
Biomedical Research Commission (ADHS16-162414) and NIH/NCI 2R01CA158079.References
[1] Boxerman JL, Schmainda KM,
Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent
extravasation significantly correlate with glioma tumor grade, whereas
uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67.
[2] Schmainda KM, Prah M, Connelly
J, Rand SD, Hoffman RG, Mueller W, et al. Dynamic-susceptibility contrast agent
MRI measures of relative cerebral blood volume predict response to bevacizumab
in recurrent high-grade glioma. Neuro Oncol 2014;16:880–8.
doi:10.1093/neuonc/not216.
[3] Stokes AM, Semmineh N,
Quarles CC. Validation of a T1 and T2* leakage correction method based on
multiecho dynamic susceptibility contrast MRI using MION as a reference
standard. Magn Reson Med 2016;76:613–25. doi:10.1002/mrm.25906.
[4] Vonken E, van Osch M,
Bakker C, Viergever M. Measurement of cerebral perfusion with dual-echo
multi-slice quantitative dynamic susceptibility contrast MRI. J Magn Reson
Imaging 1999;10:109–17.
[5] Paulson ES, Schmainda KM.
Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods:
Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors.
Radiology 2008;249:601–13. doi:doi:10.1148/radiol.2492071659.
[6] Semmineh NB, Stokes AM,
Bell LC, Boxerman JL, Quarles CC. A Population-Based Digital Reference Object
(DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for
Clinical Trials. Tomography 2017;3:41–9. doi:10.18383/j.tom.2016.00286.
[7] Boxerman JL, Schmainda KM,
Weisskoff RM. Relative Cerebral Blood Volume Maps Corrected for Contrast Agent
Extravasation Significantly Correlate with Glioma Tumor Grade, Whereas
Uncorrected Maps Do Not. Am J Neuroradiol 2006;27:859–67.
[8] Weisskoff RM, Boxerman JL, Sorensen AG, Kulke SM,
Campbell TA, Rosen BR. Simultaneous blood volume and permeability mapping using
a single Gd-based contrast injection. Proc. 2nd Annu. Meet. SMRM, San
Francisco, CA, USA: 1994, p. 279.